Acorafloxacin

Drug Profile

Acorafloxacin

Alternative Names: Avarofloxacin; JNJ-32729463; JNJ-32729463-AAA; JNJ-Q2

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Janssen
  • Developer Furiex Pharmaceuticals; Janssen
  • Class Antibacterials; Carboxylic acids; Fluorocarbons; Fluoroquinolones; Piperidines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Community-acquired pneumonia; Skin and soft tissue infections

Most Recent Events

  • 07 May 2014 Avarofloxacin is available for licensing as of 07 May 2014. http://www.furiex.com
  • 25 Feb 2013 Avarofloxacin receives Fast Track designation for Skin and soft tissue infections and Community-acquired pneumonia in USA
  • 25 Feb 2013 Avarofloxacin receives Qualified Infectious Disease Product (QIDP) designation from the US FDA for Skin and soft tissue infections and Community-acquired pneumonia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top